TY - JOUR
T1 - Layered immunity and layered leukemogenicity
T2 - Developmentally restricted mechanisms of pediatric leukemia initiation
AU - Mendoza-Castrejon, Jonny
AU - Magee, Jeffrey A.
N1 - Funding Information:
This work was supported by grants to J.A.M. from the NHLBI and NCI (R01 HL152180, R01 HL136504, and U01 CA267031), Alex's Lemonade Stand Foundation (“A” Award), the Leukemia and Lymphoma Society, the Children's Discovery Institute of Washington University and St. Louis Children's Hospital, and the Edward P. Evans Foundation. J.M‐C. is supported by an NCI training grant T32 CA113275. J.A.M. is a Leukemia and Lymphoma Society Scholar.
Publisher Copyright:
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2023/5
Y1 - 2023/5
N2 - Hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs) arise in successive waves during ontogeny, and their properties change significantly throughout life. Ontological changes in HSCs/MPPs underlie corresponding changes in mechanisms of pediatric leukemia initiation. As HSCs and MPPs progress from fetal to neonatal, juvenile and adult stages of life, they undergo transcriptional and epigenetic reprogramming that modifies immune output to meet age-specific pathogenic challenges. Some immune cells arise exclusively from fetal HSCs/MPPs. We propose that this layered immunity instructs cell fates that underlie a parallel layered leukemogenicity. Indeed, some pediatric leukemias, such as juvenile myelomonocytic leukemia, myeloid leukemia of Down syndrome, and infant pre-B-cell acute lymphoblastic leukemia, are age-restricted. They only present during infancy or early childhood. These leukemias likely arise from fetal progenitors that lose competence for transformation as they age. Other childhood leukemias, such as non-infant pre-B-cell acute lymphoblastic leukemia and acute myeloid leukemia, have mutation profiles that are common in childhood but rare in morphologically similar adult leukemias. These differences could reflect temporal changes in mechanisms of mutagenesis or changes in how progenitors respond to a given mutation at different ages. Interactions between leukemogenic mutations and normal developmental switches offer potential targets for therapy.
AB - Hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs) arise in successive waves during ontogeny, and their properties change significantly throughout life. Ontological changes in HSCs/MPPs underlie corresponding changes in mechanisms of pediatric leukemia initiation. As HSCs and MPPs progress from fetal to neonatal, juvenile and adult stages of life, they undergo transcriptional and epigenetic reprogramming that modifies immune output to meet age-specific pathogenic challenges. Some immune cells arise exclusively from fetal HSCs/MPPs. We propose that this layered immunity instructs cell fates that underlie a parallel layered leukemogenicity. Indeed, some pediatric leukemias, such as juvenile myelomonocytic leukemia, myeloid leukemia of Down syndrome, and infant pre-B-cell acute lymphoblastic leukemia, are age-restricted. They only present during infancy or early childhood. These leukemias likely arise from fetal progenitors that lose competence for transformation as they age. Other childhood leukemias, such as non-infant pre-B-cell acute lymphoblastic leukemia and acute myeloid leukemia, have mutation profiles that are common in childhood but rare in morphologically similar adult leukemias. These differences could reflect temporal changes in mechanisms of mutagenesis or changes in how progenitors respond to a given mutation at different ages. Interactions between leukemogenic mutations and normal developmental switches offer potential targets for therapy.
KW - age-biased mutation profiles
KW - age-restricted leukemias
KW - layered immunity
KW - pediatric leukemia
UR - http://www.scopus.com/inward/record.url?scp=85145395226&partnerID=8YFLogxK
U2 - 10.1111/imr.13180
DO - 10.1111/imr.13180
M3 - Review article
C2 - 36588481
AN - SCOPUS:85145395226
SN - 0105-2896
VL - 315
SP - 197
EP - 215
JO - Immunological Reviews
JF - Immunological Reviews
IS - 1
ER -